What question did this study set out to answer?

To evaluate and compare real-world efficacy and safety outcomes of tisagenlecleucel and brexucabtagene autoleucel in young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

March 24, 2025Blood AdvancesOpen Access

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

View Full Paper

Ask AI

Bookmark

Authors

HLHannah LustNorthwestern University LSLiora M. SchultzPalo Alto University SKSoyang KwonNorthwestern University

Discussion

Member takes

Implication

Retrospective study reveals comparable efficacy but higher toxicity with brexucabtagene autoleucel versus tisagenlecleucel in young adults, highlighting key safety trade-offs in CAR T therapy.

Key Points

To evaluate and compare real-world efficacy and safety outcomes of tisagenlecleucel and brexucabtagene autoleucel in young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Retrospective multicenter cohort study analyzing 70 young adult patients aged 18–26 years (tisa-cel, n = 50; brexu-cel, n = 20) from two large CAR T consortia.
Assessed complete response, 12-month relapse-free survival, overall survival, and safety outcomes including cytokine release syndrome and neurotoxicity.
Complete response rates were 80% for brexu-cel versus 88% for tisa-cel, with 12-month relapse-free survival of 46% versus 36% and 12-month overall survival of 84% versus 68%.
Brexu-cel demonstrated higher rates of cytokine release syndrome (85% vs 56%) and immune effector cell-associated neurotoxicity syndrome (40% vs 18%) compared with tisa-cel.
Multivariate analysis identified low disease burden as a predictor of improved overall survival, whereas prior exposure to inotuzumab was associated with inferior outcomes.

Cite This Study

Lust et al. (2025) studied this question.

synapsesocial.com/papers/6a9a99ff141376a341868f2f https://doi.org/10.1182/bloodadvances.2024014846

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals comparable efficacy but higher toxicity with brexucabtagene autoleucel versus tisagenlecleucel in young adults, highlighting key safety trade-offs in CAR T therapy.

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider